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mucosae with gross cervical lymphadenopathy
appeared. These new lesions caused upper airway
obstruction with respiratory distress that required a
tracheotomy and hemiglossectomy. Biopsies of skin
and mucosae confirmed Kaposi’s sarcoma. Serum
immunofluorescence assay showed a high anti-
human herpes virus-8 (HHV-8) IgG titer (1:2,560),
which demonstrated recent or active HHV-8 infec-
tion.8 Genomic DNA was prepared from sections of
paraffin-embedded blocks of the lesion. HHV-8
detection was performed by polymerase chain reac-
tion (PCR) using primers KS1 and KS2.9 An amplifi-
cation product of 233 bp was obtained in samples,
indicating the presence of HHV-8 virus in neoplastic
tissue. Immunosuppressive therapy was discontinued
on day + 479, but the lesions did not remit. The
patient died from massive lung hemorrhage on day
+486. Permission for post mortem examination was
denied, and the cause of the lung hemorrhage could
not be determined.
KS has a negligible incidence in the general popu-
lation, but has been observed in up to 6% of patients
undergoing organ transplantation. Moreover, the
incidence of KS is higher in patients treated with CsA
and some authors have suggested that this associa-
tion might reflect a state of overimmunosuppression
rather than a specific effect of the molecule.1-4 Some
studies have found DNA sequences of viral agents in
tissue samples of KS and suggest the existence of a
new herpesvirus, the human herpesvirus-8 or Kaposi’s
sarcoma-associated herpesvirus.4,6,9,10 The high anti-
HHV-8 IgG titer and the presence of HHV-8 virus in
neoplastic tissue of our patient demonstrated recent
or active HHV-8 infection.
In our view, prolonged therapy with CsA and oth-
er immunosuppressive drugs and the immune defi-
ciency associated with severe chronic GVHD may
have predisposed to the development of KS in the
case described here.
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Platelet cryopreservation using second-
messenger effectors and low-dose (2%)
dimethyl sulfoxide. In vitro evaluation of
post-thawing platelet activity with
the platelet function analyzer
Second-messenger effectors (ThromboSol®),
together with low-dose dimethyl sulfoxide (DMSO)
(2%), are described as a new cryopreservation solu-
tion. The solution allows high yield recovery of cryo-
preserved platelets with a residual platelet function
equal or superior to that of 6% DMSO-cryo-
preserved platelets. The hemostatic function of cryo-
preserved platelets was measured by PFA-100™. 
Sir,
At present, 5-6% DMSO is considered the most
effective cryopreserving agent in terms of cell yield
and residual function of recovered platelets.1 Recent-
ly, second messenger effectors (ThromboSol®) (TC)
have been used combined with low-dose (2%)
DMSO, to cryopreserve platelet concentrates at
–80°C for clinical use.2-4 The aim of the present work
was to compare the yield and function of platelets
frozen with either 6% DMSO or TC-2% DMSO. 
An intriguing problem is the in vitro measurement of
objective parameters capable of predicting the in vivo
hemostatic function of the recovered platelets. Mim-
icking physiologic platelet-subendothelial interactions,
the platelet function analyzer (PFA100™) measures in
vitro closure time, a surrogate index of in vivo bleeding
time.5-8 Having previously developed a procedure to
use PFA100™ to assess platelet function in platelet
concentrates,9 we used this procedure to compare
residual platelet function in concentrates frozen using
the two protocols. Yield, morphology and adhesion
capacity were evaluated altogether. Thawed platelets
were evaluated prior to and following a single wash-
ing procedure to remove about 95% of the TC and
DMSO. Platelets were obtained by buffy-coat frac-
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tionation of whole blood units collected in CPDA. 
ThromboSol® (TC) (LifeCell Corp. Branchburg, NJ,
USA) in pure DMSO containing amiloride (Na+ H+
exchange inhibitor), adenosine, and sodium nitro-
prusside, which are cAMP and cGMP stimulators,
respectively. TC was added (1:50v/v) to the platelet
suspension. After mixing, the suspension was placed
at -80°C. Platelet bags were thawed by immersion
into a 38°C water bath, under continuous agitation
until complete dissolution of the solid phase. The 6%
DMSO frozen platelets were obtained and thawed
using standard protocols. 
Platelet recovery was assessed by cytometric platelet
count (Sysmex K-800, Toa Medical Electronics, Kobe,
Japan). Platelet morphology was evaluated using a
phase-contrast microscopy equipped with a 40X
objective. The primary platelet hemostatic capacity
(adhesion phase) was investigated by pipetting 50 µL
of platelets (100x109/L) over the surface of a cleaned
240x240 mm glass coverslip. After incubation in a
moist chamber for 30 minutes, non-adherent cells
were removed and the adherent cells were counted
using a phase-contrast microscope equipped with a
40X objective. Platelet function was measured by
PFA100™, following reconstitution of whole blood.
Platelet function was defined as closure time (C-ADP
or C-epinephrine, accordingly to the cartridge used)
or as PFA-Index (PFA-I), calculated using the follow-
ing formula:
[total flow volume (µL) : flow rate (µL/min)] x closure or elapsed time (sec)
PFA-PI =
100
After thawing and washing, platelet recovery, dis-
coid platelets, and the absolute number (four fields)
of glass-adherent cells were measured (Figure 1). The
mean results were respectively 71, 69, and 179 for
the TC-treated platelets and 57, 54, and 67 for the
DMSO-treated platelets. The corresponding p values
were: < 0.005, <0.001, and < 0.001.
The PFA100™ TM results, evaluated as C-ADP, C-
epinephrine, and PFA-PI are reported in Table 1.
Following cryopreservation, the platelet function
was greatly diminished for both TC- and DMSO-
treated platelets in comparison with fresh platelets.
Platelet function of the TC-treated cells was partial-
ly restored though, after washing. The re-establish-
ment of PFA-100 activity was greater when the ADP
cartridge was used. Using the ADP cartridge, the TC-
treated platelets displayed a statistically significant
improvement in both closure time and PFA-PI as
compared to the DMSO-treated washed cells
(p<0.05). Using the epinephrine system, the DMSO-
treated platelets displayed a statistically significant
improvement in PFA-PI compared to the TC-treated
platelets regardless of the washing step.
886
Haematologica vol. 85(8):August 2000
scientific correspondence
Table 1. PFA100™ measurement of functional activity.
ThromboSol-Treated Platelets DMSO-Treated Platelets
Thawed Thawed
Fresh Unwashed Washed Unwashed Washed
Cartridge ADP epinephrine ADP epinephrine ADP epinephrine ADP epinephrine ADP epinephrine
Closure Time1 (sec) 96.7 139.9 3003 3009 202.03 268.39 268.43 212.07 253.93,5 229.19
±5.2 ±33.8 ±0.0 ±0.0 ±45.3 ±28.2 ±41.9 ±80.5 ±41.2 ±59.1
PFA-Index1 2.85 3.90 14.403 13.849 6.962 10.379 7.563,6 6.298,11 9.533,4 8.208,10
±0.71 ±1.63 ±0.57 ±0.67 ±3.00 ±2.84 ±2.61 ±2.74 ±2.71 ±3.61
1Mean value ± standard deviation, n=8; 2p<0.005 for the values for cryopreserved samples as compared to the values for fresh samples. 3p<0.001 for the values
for cryopreserved samples as compared to the values for fresh samples. 4p<0.05 for the values for TC-treated samples as compared to the paired values for
DMSO-treated samples. 5p<0.005 for the values for TC-treated samples as compared to the paired values for DMSO-treated samples. 6p<0.001 for the values for
TC-treated samples as compared to the paired values for DMSO-treated samples.7p<0.05 for the values for cryopreserved samples as compared to the values for
fresh samples. 8p<0.005 for the values for cryopreserved samples as compared to the values for fresh samples. 9p<0.001 for the values for cryopreserved sam-
ples as compared to the values for fresh samples. 10p<0.05 for the values for TC-treated samples as compared to the paired values for DMSO-treated samples.
11p<0.001 for the values for TC-treated samples as compared to the paired values for DMSO-treated samples. Comparison by the two-tailed paired t-test.
Figure 1. Glass adhesion capacity of cryopreserved
platelets.  Platelets were cryopreserved with TC or DMSO
as described in the Design and Methods section. The
platelet samples were analyzed for adherence to glass pri-
or to freezing, following thawing, and following a post-thaw
wash step as described in the Design and Methods section.
The data are expressed as the mean (± standard deviation)
total number of platelets which adhered to a constant area
of glass surface as described in the Design and Methods
section. *p<0.001 for the values for cryopreserved samples
as compared to the values for fresh platelets. #p<0.05 for
the values for cryopreserved samples as compared to the
values for fresh platelets. @p<0.001 for the values for TC-
treated samples as compared to the values for DMSO-treat-
ed samples.
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In conclusion, quantitative, morphologic and func-
tional data, particularly when measured in vitro as
PFA-PI using an ADP cartridge, showed that TC-cry-
opreserved platelets are at least as good as, and pos-
sibly superior to, DMSO-cryopreserved platelets.
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Anti-D immunoglobulin in children with newly
diagnosed immune thrombocytopenic purpura:
a pilot study
Treatment options for childhood immune throm-
bocytopenic purpura (ITP) include observation,
steroids, intravenous gammaglobulin (IVIG) and
splenectomy.1 Recent studies2-4 have shown that
anti-D increases the platelet count in children with
ITP but that the time to achieve a platelet count
≥ 20,000/µL is significantly longer than following
IVIG.5 We gave anti-D as a single intravenous dose
of 50 µg/kg to 10 consecutive Rh positive children
with newly diagnosed ITP.
Sir,
Newly diagnosed patients aged 6 months to 18
years with a clinical diagnosis of ITP based on histo-
ry, physical examination and isolated thrombocy-
topenia with a normal blood smear, were eligible for
entry into the study. Initial evaluation consisted of a
history and physical examination, complete blood
count with differential, blood type and direct
Coombs’ test. After informed consent had been
obtained, all Rh positive, Coombs’ negative patients
were treated with one dose of intravenous anti-D
(Winrho-SD, Univax Biologics, Inc, Rockville, MD,
USA) 50 µg/kg over 5 minutes. Complete blood
counts were done every 12 hours until the platelet
count was ≥ 20,000/µL at which point the patient
was discharged home. Response was defined as an
increase in platelet count to ≥ 20,000/µL with cessa-
tion of bleeding. This study was approved by the insti-
tutional review board at Baystate Medical Center,
Springfield, Massachusetts.
The patients’ characteristics and results of treat-
ment are presented in Table 1. Platelet counts for the
first 40 hours post-anti-D are shown in Figure 1. All
10 patients responded to anti-D. The mean time to
platelet count ≥20,000/µL was 22.3±11.4 hrs (medi-
an 16.4 hrs; range 12-39.5 hrs). Median post-anti-D
peak platelet count was 253,000/µL occurring at a
median of 8 days post-treatment. The average drop
in hemoglobin was 1.27 g/dL ±0.7. Three patients
were retreated for platelet counts < 20,000/µL. No
allergic complications occurred, and no patients
required transfusions secondary to anti-D-induced
hemolysis. Two patients had mild headache 2-3
hours post-infusion; one also had emesis. All symp-
toms resolved with acetaminophen and diphenhy-
dramine. Therapeutic options for childhood ITP
remain controversial5-7 and include IVIG, corticos-
teroids, anti-D or less commonly splenectomy. Anti-
D has potential advantages over IVIG: lower cost8
and fewer side effects (headache, vomiting, aseptic
meningitis).3,4,9 The presumed method of action for
anti-D is saturation of Fc receptors in the spleen with
antibody-coated red blood cells.
Blanchette et al.5 randomized 146 children with ITP
to receive low dose IVIG (0.8 g/kg), high dose IVIG (1
g/kg/day x2), intravenous anti-D (25 µg/kg/day x 2)
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